Metraipolis › archive › dc_c5033e475261
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41169385
- DOI
- 10.3389/fimmu.2025.1667793
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-09T07:23:32.793Z
- SHA-256 of the archived text
bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa- Stable URL of this page
https://metraipolis.com/documento/dc_c5033e475261
How to cite
First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385 — Europe PMC (en), https://europepmc.org/article/MED/41169385 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c5033e475261 (Metraipolis archive dc_c5033e475261, sha256 bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa)
BibTeX
@misc{dcc5033e475261,
title = {First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular… — Europe PMC PMID:41169385},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41169385},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c5033e475261; sha256 bcb8a9a1f9317c956da9699bb5c4d44bdd87f3ed096e79688d8c1dd607c911aa},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41169385. Agents can read the archived copy with the MCP tool read_document.